UK-India Partnership for the control of FMD and PPR
Lead Research Organisation:
The Pirbright Institute
Department Name: Livestock Infectious Diseases
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
- The Pirbright Institute (Lead Research Organisation)
- Indian Council of Agricultural Research (Collaboration, Project Partner)
- Indian Immunologicals Ltd (Collaboration)
- Tamil Nadu Veterinary and Animal Sciences University (Collaboration)
- National Institute of Animal Biotechnology (Collaboration)
- Indian Veterinary Research Institute (Collaboration, Project Partner)
- National Research Centre on Equines (Project Partner)
Publications
Getachew B
(2018)
Monoclonal antibody resistant mutant of Peste des petits ruminants vaccine virus.
in Virusdisease
Kumar KS
(2014)
Molecular characterisation of lineage IV peste des petits ruminants virus using multi gene sequence data.
in Veterinary microbiology
Parida S
(2015)
Peste des petits ruminants
in Veterinary Microbiology
Parida S
(2015)
Peste des Petits Ruminants Virus
Sen A
(2014)
Detection of subclinical peste des petits ruminants virus infection in experimental cattle
in VirusDisease
| Description | 1. Collaboration between 4 Institutes in India for PPR work has been initiated 2.Collaboration extended to NIVEDI, Bangalore 3. Joint Publications have been made 4.Two BBSRC-DBT FADH project on FMD and PPR were successfully achieved. 5. A BBSRC follow on grant had been awarded to work with Indian Immunologicals. |
| Exploitation Route | Two BBSR-DBT FADH grants and one follow on grant on PPR and FMD were funded. Under these research grants we have developed PPR DIVA vaccine and demonstrated how the duration of immunity can be increased for FMD vaccine and will help in the disease control programme. |
| Sectors | Agriculture, Food and Drink,Education,Government, Democracy and Justice,Manufacturing, including Industrial Biotechology |
| Description | Indian Immunologicals, an Industry ( manufacturer) for FMD and PPR vaccines became collaborator to the Pirbright Institute. Further recently working with indusrial partner we showed that TLR III adjuvant is capable of increasing the duration of immunity. Similarly in FADH project which was follow on to this partnering award helped us to develop PPR DIVA vaccines. All the results has been informed industries through FAO/OIE expert group/vaccine producers meeting. Working with partners from IVRI minimum four scientists were trained on reverse genetics technique. Couple of paramyxo viruses were rescued. Several lead talks on FMD and PPR control have been delivered by the PI at TANUVAS, Chennai, ASC, Delhi, IAVMI, Bareilly, Indian veterinary association at Delhi and Virocon at Delhi which have impacts on veterinarians, policy makers and scientists/. |
| First Year Of Impact | 2013 |
| Sector | Agriculture, Food and Drink,Education,Government, Democracy and Justice,Manufacturing, including Industrial Biotechology |
| Impact Types | Policy & public services |
| Description | An effective vaccination programme for the eradication of foot-and-mouth disease from India |
| Amount | £673,500 (GBP) |
| Funding ID | BB/L004828/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2014 |
| End | 02/2018 |
| Description | FADH PPR project -Understanding the immune mechanism of host disease resistance and development of marker vaccines and DIVA tests for Peste des Petits Ruminants (PPR) |
| Amount | £351,000 (GBP) |
| Funding ID | BB/L004801/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2014 |
| End | 07/2018 |
| Description | Improving the duration of immunity for FMD vaccine |
| Amount | £201,000 (GBP) |
| Funding ID | BB/N012682/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2016 |
| End | 05/2017 |
| Title | Benifit of addition of TLR III to existing FMD vaccine |
| Description | We have demonstrated that TLR III adjuvants along with existing oil adjuvants provides longer duration immunity. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | This will fulfill the lacuna of short living immunity of FMD inactivated vaccines |
| Title | Use of reverse genetics to develop PPR DIVA vaccines |
| Description | Reverse genetics technique has been established for PPR virus in our laboratory. As PPR vaccine is a live attenuated virus, it is not possible to differentiate between vaccinated and infected animals (DIVA) in existing antibody assays. However using reverse genetics technique we have manipulated/mutated residues in the full-length cDNA of virus and rescued the live attenuated vaccine strain which worked as a DIVA vaccine. Using this technique a GFP ( Green fluorescent protein) has been introduced into the virulent PPR virus that helped to follow the virus in the infected goats. Similarly using this technique we have modified the existing live attenuated viruses ( Nigeria 75/1) and Sungri 96/1) in to recombinant marker vaccines that enables to differentiate between infection and vaccination ( DIVA). So we have demonstrated that reverse genetics tool can be used to study the pathogenesis and to develop the marker vaccines. This technique can be adapted for other negative strand viruses to design the DIVA vaccines. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | PPR DIVA vaccine developed that can differentiate between vaccinated and infected animals. This will be helpful to know the efficacy of vaccine by knowing the presence antibodies in animal is due to vaccination or infection. This will reduce the eradication time and will facilitate to declare freedom of diseases as soon as Possible without long waiting period. |
| Description | Adjuvants study-FMD vaccine at Indian Immunologicals |
| Organisation | Indian Immunologicals Ltd |
| Country | India |
| Sector | Private |
| PI Contribution | Conducted screening of 8 adjuvants with FMD vaccine in cattle and analyse the samples originated from the experiments. 4 selected adjuvants were tested in cattle at the Pirbright Institute and TLR III adjuvant was found as the best one. Under Follow on grant 12 cattle were vaccinated with existing vaccine with oil adjuvant and 12 cattle were vaccinated with oil and TLR III adjuvants. The protective immununity was assessed from the virus neutralizing antibody status. By 6 months post-vaccination only 17% of cattle were having protective antibodies (1:45 dilution) in conventional vaccine group whereas 80% cattle were having protective neutralizing titer (1:45) in TLR adjuvanted group. Therefore it is clear that adding TLR adjuvant one can increase the duration of immunity up to 6 months. |
| Collaborator Contribution | Facilitate the animal experiments at their High containment |
| Impact | Conducted screening of 8 adjuvants with FMD vaccine in cattle and analyse the samples originated from the experiments. 4 selected adjuvants were tested in cattle at the Pirbright Institute and TLR III adjuvant was found as the best one. Under Follow on grant 12 cattle were vaccinated with existing vaccine with oil adjuvant and 12 cattle were vaccinated with oil and TLR III adjuvants. The protective immununity was assessed from the virus neutralizing antibody status. By 6 months post-vaccination only 17% of cattle were having protective antibodies (1:45 dilution) in conventional vaccine group whereas 80% cattle were having protective neutralizing titer (1:45) in TLR adjuvanted group. Therefore it is clear that adding TLR adjuvant one can increase the duration of immunity up to 6 months. |
| Start Year | 2016 |
| Description | IVRI, Mukteswar |
| Organisation | Indian Veterinary Research Institute |
| Country | India |
| Sector | Public |
| PI Contribution | 1. DIVA vaccine and DIVA test development. 2.Early pathogenesis study for PPR.3. Sharing of Knowledge 4.Joint publications |
| Collaborator Contribution | Development LAMP technique for PPR |
| Impact | 1. Development of DIVA vaccines and DIVA tests 2. Early pathogenesis study showed that PPR virus first replicates in Tonsils 3. LAM assay developed for PPR |
| Start Year | 2014 |
| Description | Indian Veterinary Research Institute (IVRI), Bareilly |
| Organisation | Indian Veterinary Research Institute |
| Country | India |
| Sector | Public |
| PI Contribution | 1. Development of PPR DIVA vaccine and DIVA tests 2. Early pathogenesis study |
| Collaborator Contribution | Development of Biosensor diagnostic assay for PPR |
| Impact | Joint publications. Sharing of knowledge. |
| Start Year | 2014 |
| Description | NIAB, Hyderabad |
| Organisation | National Institute of Animal Biotechnology |
| Country | India |
| Sector | Public |
| PI Contribution | DIVA vaccine and DIVA tests |
| Collaborator Contribution | SNP study for disease resistance |
| Impact | Development of DIVA vaccine and DIVA tests for PPR |
| Start Year | 2014 |
| Description | PDFMD Mukteswar |
| Organisation | Indian Council of Agricultural Research |
| Department | Foot and Mouth Disease Control Programme |
| Country | India |
| Sector | Charity/Non Profit |
| PI Contribution | Received 187 field viruses and antisera against existing vaccine viruses (O,A and ASia1). r1 value were obtained from 2D virus neutralisation assay. The joint publication has been made. |
| Collaborator Contribution | Field sample provision |
| Impact | Joint publications |
| Start Year | 2012 |
| Description | TANUVAS, INdia |
| Organisation | Tamil Nadu Veterinary and Animal Sciences University |
| Country | India |
| Sector | Academic/University |
| PI Contribution | 1. Development of DIVA vaccine and DIVA test. 2. Early pathogenesis study.3 Contributed to Transcriptome analysis carried out by TANUVAS |
| Collaborator Contribution | Transcriptome study for disease resistance in different breed of goats, sheep and large ruminants |
| Impact | 1.Development of DIVA vaccine.2. Development of DIVA tests 3. Early pathogenesis study showed that Virus first replicate in tonsils.4. High basal level of SLAM is present in large ruminants in comparison to small ruminants and may be therefore large ruminants are more resistant to the PPR. |
| Start Year | 2014 |
| Title | PPR DIVA vaccine |
| Description | We ahve developed two PPR live attenuated DIVA vaccines that can differentiate between vaccinated and infected animals. |
| IP Reference | PCT/GB2019/053641,WO2020128496 |
| Protection | Patent application published |
| Year Protection Granted | 2020 |
| Licensed | Commercial In Confidence |
| Impact | Till date there is no PPR vaccine avalable that can differentiate between vaccination and infection. This causes a huge issue on eradication of the didease and declare freedom from the disease. Therefore our newly develped chimeric live attenauted PPR vaccine and DIVA tests can differentiate between vaccination and infection which is a great achievement for ongoing PPR eradication. Please see detail from the below web. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020128496 |
| Description | Annual project meeting FADH PPR project at IVRI India- February 2018 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Study participants or study members |
| Results and Impact | The 3rd Annual project meeting for FADH project was carried forward at IVRI between project partners. The work progress has been discussed and further meetings at TANUVAS, India and Pirbright, UK are planned. |
| Year(s) Of Engagement Activity | 2018 |
| Description | FMD workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | Workshop on FMD control was conducted at PDFMD Mukteswar. Minimum 10 scientists from Pirbright and 10 from PDFMD had joined and delivered talks and discussed the FMD control. Agreement had been obtained to fr joint funding and publication and as shown further funding from DBT and BBSRC had been obtained. |
| Year(s) Of Engagement Activity | 2014 |
| Description | Faculty talk at IVRI, India in PPR DIVA vaccine and DIVA tests development |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Satya Parida delivered an invited talk on PPR DIVA vaccine development using reverse genetics technique. Scientists and post graduate students were enjoyed the talk which sparked many questions and discussions afterwards and the joint Director of IVRI expressed interest on the work and further meetings. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Initiation of a mass vaccination campain ( 2018) in TamilNadu, India |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Scientists from The Pirbright Institute's Vaccine Differentiation group have recently returned from Chennai in India, where they conducted a mass peste des petits ruminants (PPR) vaccination campaign and awareness programme. They joined scientists from four specialist organisations; Tamil Nadu Veterinary and Animal Sciences University (TANUVAS), Indian Veterinary Research Institute (IVRI), National Institute of Animal Biotechnology (NIAB) and National Institute of Veterinary Epidemiology and Disease Informatics (NIVEDI). Peste des petits ruminants (PPR), also known as goat plague, is highly contagious and infects small ruminants such as sheep and goats, causing up to 90% mortality. The disease is prevalent across large parts of Africa, the Middle East, India and China and is estimated to cost between US$1.4 billion and US$2.1 billion globally each year. In 2017, the Food and Agricultural Organization (FAO) and the World Organisation for Animal Health (OIE) introduced a global eradication programme to reduce the devastating impact PPR has on the economy and food security of affected countries. "Over 40 vets joined our vaccination campaign in the Tanir Kulum village of Tiruvallur District, TaminNadu (close to Chennai), where we administered vaccines to over 400 sheep and goats in a single day. We also ran an awareness camp where we provided farmers and vets alike with expert guidance on diagnosing clinical signs of PPR and what measures they could take to reduce its spread", said Professor Satya Parida from Pirbright, who led the collaborative effort with Dr Dhinakar Raj from TANUVAS. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.pirbright.ac.uk/news/2018/09/pirbright-scientists-run-vaccination-campaign-eradicate-pes... |
| Description | Invited lead talk and Chairing brain sterming session on FMD vaccine and control at international conference at Hyderabad Organised by NIAB |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | 1.Invited lead talk on Epidemiology of PPR.2. Chairing brain sterming session on FMD vaccine and control at international conference on Infectious animal diseases at Hyderabad Organised by NIAB |
| Year(s) Of Engagement Activity | 2014 |
| Description | Invited lead talk at Indian Association of Veterinary Anatomists (IAVA), Orissa university of agriculture and Technology, 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Study participants or study members |
| Results and Impact | A talk has been delivered on new generation FMD and PPR vaccines |
| Year(s) Of Engagement Activity | 2017 |
| Description | Invited talk at Agricultural Science congress at New Delhi, India, February-2019- Use of reverse genetics to study the early pathogenesis and to develop marker vaccines for PPR |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | 1. In a DBT-BBSRC FADH grant, The Pirbright Institute in collaboration with four Indian partners (TANUVAS, IVRI, NIAB and NIVEDI) has developed a PPR vaccine, which will be the first to differentiate between infected and vaccinated animals (DIVA), for which a patent application has been filed. Scientists have manipulated in the genome of PPR full length cDNA and rescued the DIVA vaccine virus using reverse genetic technique. Further this vaccine has been tested in goats providing full safety and potency upon virulent virus challenge. In contrast to current vaccine, this new DIVA vaccine can differentiate between naturally infected and vaccinated animals, therefore will help in meaningful assessment of vaccine coverage and epidemiological surveillance based on serology, in turn increasing the efficiency of control programmes. 2. Little is known about the early events in the development of peste des petits ruminants (PPR) virus (PPRV) infection. The current dogma is that similar to RPV, PPRV replicates primarily in the epithelium of the respiratory tract before disseminating throughout the host. However, our investigations, using intranasal inoculation of PPRV containing GFP (Green Fluorescent Protein) to mimic natural infection, indicate this is not the case and that immune cells in the pharyngeal tonsil is the primary target. This is a ground breaking discovery which changes the PPR pathogenesis. This infectious GFP virus is made from a synthetic cDNA of field virus (PPRV/Mor-08) using reverse genetics technique under FADH grant. The presentation sparked questions and discussions after the talk. Two PPR DIVA vaccines developed and the mechanism of PPR virus pathogenesis explained. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Invited talk on Efficacy FMD vaccine using TLR adjuvants at NVRQS, South Korea |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Satya Parida was invited to deliver a talk on FMD vaccine using TLR adjuvants. Since 2010 South Korea is facing FMD outbreak and preparing themselves to prepare their own FMD Vaccine. As we have identified TLR 3 is a good adjuvant for stimulating humoral and cell-mediated response I received sparked questions and discussion afterwards. Recently I have received queries for providing details about the adjuvants so that they can include this adjuvant to their vaccine. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Invited talk on Epidemiology and vaccine development using reverse genetics techniques at Institute of Life science, Bhubaneswar India. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Invited talk on Epidemiology and vaccine development using reverse genetics techniques at Institute of Life science, Bhubaneswar India delivered on 5th of Feb, 2018. Students and scientists were encouraged to take forward the approach for human disease and some request obtained to visit our lab at the Pirbright, Institute. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Invited talk on new generation FMD vaccines at NIAB faculty |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | Delivered an invited talk on new generation FMD vaccines to inform the collaborator how TLR III adjuvant lingers the duration of immunity. The talk initiated sparking questions after the talk. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Invited talk on reverse genetics to develp marker vaccine for FMD and PPR at OUAT, Bhubanesawar, India |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | Delivered a talk on development of viral vector vaccine for FMD and PPR and the same approach how could be adapted for other diseases. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Oral presentation at EUFMD meeting, Burgo, Italy on Longer duration of Immunity of FMD vaccine |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Talk on duration immunity for FMD vaccine and how it can be double by adding a TLR3 adjuvant to the correct vaccine formulation. This sparked questions and discussion afterwards. vaccine industries were keen on this. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Project close meeting at TANUVAS, Chennai July 2018- Delivering talk on outcome of the project |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The project team held their final workshop at TANUVAS, which concluded a four year Farmed Animal Disease and Health (FADH) grant joint funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and the Indian Government's Department of Biotechnology (DBT). "This grant has enabled us to collaborate with four organisations across India, and ensured that our research can be applied in the field to aid the campaign for PPR global eradication", said Professor Parida.The project covered many areas of research which are essential for understanding PPR and creating tools to help control and prevent the disease. The team have now filed a patent application for their newly developed PPR vaccine, which is the first to differentiate between vaccinated and infected animals (DIVA) - a quality that enables livestock owners to protect their animals whilst continuing to trade. The team have also investigated how the PPR virus (PPRV) infects sheep and goats and how their immune systems respond. By inserting green fluorescent protein into virulent PPRV and administering the modified virus to goats, they demonstrated that PPRV primarily infects the tonsils, challenging the earlier belief that the virus first replicates in the respiratory tract epithelial cells. The collaborative project has also generated better diagnostic tests for use in the field and laboratory, and preliminary research has identified why some Indian breeds of goats and sheep are resistant to the disease, which could help scientists to create PPRV resistant breeds in the future. Project partners, scientists from the University and 40 field veterinarians have joined the meeting. An awareness training has been conducted on PPR disease and eradication for these field veterinarians. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.pirbright.ac.uk/news/2018/09/pirbright-scientists-run-vaccination-campaign-eradicate-pes... |